VNDA: חוב לטווח קצר של החברה Vanda Pharmaceuticals

Vanda Pharmaceuticals (VNDA) develops medications for the therapy of central nervous system disorders. The loss of patent protection for core assets is driving up legal costs, which reduces profitability, and the 0.00 market value of the asset clearly shown on this chart confirms the current trend. Successes with Fanapt and Hetlioz, along with measures to prevent a hostile takeover of the business, are creating positive momentum.

Analyzing the resilience of Vanda Pharmaceuticals (VNDA) to market shocks requires an assessment of its liquidity. High physician confidence in its schizophrenia medications ensures a stable cash flow. The book value of short-term debt illustrates obligations maturing within one year. This metric measures the company's ability to service current loans without raising emergency capital. A low level of this indicator confirms the issuer's financial reliability.